Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis

被引:0
作者
Carlo Lazzaro
Leonardo Lopiano
Dario Cocito
机构
[1] Studio di Economia Sanitaria,UOA Neurologia 2, Dipartimento di Neuroscienze
[2] University of Turin,undefined
来源
Neurological Sciences | 2014年 / 35卷
关键词
Chronic inflammatory demyelinating polyneuropathy; CIDP; Immunoglobulin; SCIG; IVIG; Cost-minimization analysis;
D O I
暂无
中图分类号
学科分类号
摘要
Prior researches have suggested that home-based subcutaneous immunoglobulin (SCIG) is equally effective and can be less expensive than hospital-based intravenous immunoglobulin (IVIG) in treating chronic inflammatory demyelinating polyneuropathy (CIDP) patients. This economic evaluation aims at comparing costs of SCIG vs IVIG for CIDP patients in Italy. A 1-year model-based cost-minimization analysis basically populated via neurologists’ opinion was undertaken from a societal perspective. Health care resources included immunoglobulin; drugs for premedication and complications (rash, headache, and hypertension) management; time of various health care professionals; pump for SCIG self-administration; infusion disposables. Non-health care resources encompassed transport and parking; losses of working and leisure time for patients and caregivers. Unit or yearly costs for resources valuation were mainly obtained from published sources. Costs were expressed in Euro (€) 2013. An extensive one-way sensitivity analysis (OWSA) and a scenario SA tested the robustness of the base case findings. Overall costs per patient amount to €49,534.75 (SCIG) and €50,895.73 (IVIG); saving in favour of SCIG reaches €1360.98. For both SCIG and IVIG, the cost driver was immunoglobulin (94.06 vs 86.06 % of the overall costs, respectively). Sensitivity analyses confirmed the consistency of the baseline results. SCIG may be a cost-saving therapy for Italian CIDP patients.
引用
收藏
页码:1023 / 1034
页数:11
相关论文
共 81 条
  • [1] van Schaik IN(2005)Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy Cochrane Database Syst Rev 25 71-87
  • [2] van den Berg LH(2007)Chronic inflammatory demyelinating polyneuropathy Neurol Clin 66 677-680
  • [3] de Haan R(1999)Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in South-East England J Neurol Neurosurg Psychiatry 46 910-913
  • [4] Vermeulen M(1999)Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia Ann Neurol 8 157-165
  • [5] Lewis RA(2001)Chronic polyneuropathies in Vest-Agder, Norway Eur J Neurol 78 1349-1353
  • [6] Lunn MPT(2007)Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy J Neurol Neurosurg Psychiatry 16 150-152
  • [7] Manji H(2011)The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin J Peripher Nerv Syst 17 426-428
  • [8] Choudhary PP(2012)Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies J Peripher Nerv Syst 30 21-31
  • [9] Hughes RAC(2009)Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b Neurol Sci 6 429-462
  • [10] Thomas PK(1982)Cost-of illness methodology: a guide to current practices and procedures Milbank Mem Fund Q Health Soc 5 13-23